Yükleniyor... / Loading...
This study examines the use of N-Acetyl Cysteine (NAC) in people with retinitis pigmentosa, an inherited eye disease. It was open to adults over 18 who had been diagnosed with RP. It was conducted in Phase 1 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: All subjects must meet the following criteria to be eligible for study entry: * Signed informed consent and authorization of use and disclosure of protected health information * Age \>18 years * Patients diagnosed with RP by the investigators, based on clinical phenotype and diagnostic tests Exclusion Criteria: Subjects who meet any of the following criteria will be ineligible for study entry: * Patients with concurrent retinal pathologies that result in vision loss, including but not limited to retinal vein occlusion, diabetic retinopathy and neovascular age-related macular degeneration. If one eye does not have any retinal pathology other than RP, it may be enrolled in the study. * Patients with uncontrolled arterial hypertension defined as diastolic blood pressure \> 95 mm Hg or systolic blood pressure \> 160 mm Hg despite medical therapy.